| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Plasma kallikrein |
|---|
| Ligand | BDBM263240 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | Inhibitory Activity Assay |
|---|
| IC50 | 7.31±0 nM |
|---|
| Citation |  Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST; Miller, I; Novak, AR; Smith, AJ; Stocks, MJ Heterocyclic derivates US Patent US9533987 Publication Date 1/3/2017 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Plasma kallikrein |
|---|
| Name: | Plasma kallikrein |
|---|
| Synonyms: | Fletcher factor | KLK3 | KLKB1 | KLKB1_HUMAN | Kallikrein | Kininogenin | Plasma kallikrein heavy chain | Plasma kallikrein light chain | Plasma prekallikrein |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 71391.16 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P03952 |
|---|
| Residue: | 638 |
|---|
| Sequence: | MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF
SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD
MRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK
VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFF
TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV
DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI
AYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG
GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG
NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI
PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE
GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
|
|
|
|---|
| BDBM263240 |
|---|
| n/a |
|---|
| Name | BDBM263240 |
|---|
| Synonyms: | 3-cyclopropyl-1-(5-methoxy-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1h-pyrazole-4-carboxylic acid (1-amino-isoquinolin-6-ylmethyl)-amide | US9533987, example 25 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C28H31N7O2 |
|---|
| Mol. Mass. | 497.5914 |
|---|
| SMILES | COc1cc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C2CC2)cnc1N1CCCC1 |
|---|
| Structure | 
|
|---|
Search and Browse
